TARDBP and amyotrophic lateral sclerosis: Our initial observations suggested that control and patient iPSC-derived neurons with either TARDBP or C9ORF72 ALS mutations were indistinguishable, based on cell morphology (Fig. 2a), up to the latest time point investigated (10 weeks post plating).